文献速递骨软组织肉瘤与黑色素瘤

达拉非尼联合曲美替尼治疗BRAF V600突变晚期黑色素瘤的IIIb期研究

Efficacy, safety and factors associated with disease progression in patients with unresectable (stage III) or distant metastatic (stage IV) BRAF V600-mutant melanoma: An open label, non-randomized, phase IIIb study of trametinib in combination with dabrafenib.
PubMed 文献 · Eur J Cancer · 2021-07-06

法国多中心单臂开放标签IIIb期研究纳入856例不可切除III期或转移性BRAF V600突变黑色素瘤患者,接受达拉非尼联合曲美替尼治疗,中位无进展生存期(PFS)为8.02个月(95%CI 7.33-8.77),ECOG PS≥1、LDH升高、≥3个转移部位和脑转移与更短PFS独立相关,无脑转移且ECOG=0且转移部位<3的患者6个月和12个月PFS概率最高。

要点

  • 达拉非尼联合曲美替尼在真实世界样人群中中位PFS为8.02个月。
  • ECOG PS≥1、LDH升高、≥3个转移部位和脑转移与更短PFS相关。
  • 无脑转移、ECOG=0且转移部位<3的患者6个月和12个月PFS率分别为83%和56%。

核心结论

  • 达拉非尼联合曲美替尼在接近真实世界的晚期BRAF V600突变黑色素瘤患者中证实疗效,脑转移是独立的不良预后因素。

主要发现

  • 中位PFS为8.02个月(95%CI 7.33-8.77)。
  • 与更短PFS显著相关的因素包括ECOG PS≥1、LDH升高、≥3个转移部位和脑转移。
  • 无脑转移、ECOG=0且转移部位<3的患者6个月PFS概率为83%(95%CI 76-87),12个月为56%(95%CI 47-64)。

临床怎么用

  • 对于BRAF V600突变晚期黑色素瘤患者,达拉非尼联合曲美替尼是有效选择,尤其需关注脑转移、LDH升高、ECOG PS≥1及多转移部位患者的不良预后。

局限性

  • 单臂设计缺乏对照,疗效评估为局部判定未经过中心审核。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: BRAF and MEK inhibitors combination, including dabrafenib (D) and trametinib (T) have transformed the treatment of BRAF V600-mutant advanced melanoma patients, including patients with brain metastasis (BM). In a large phase IIIb, single-arm, open-label, multicenter French study, we assessed safety, response to treatment, progression-free survival (PFS) and factors associated with progression, and stratified the population into risk groups. METHODS: Patients with unresectable, advanced, BRAF V600-mutant melanoma were included, including those with the presence of BM, Eastern Cooperative Oncology Group Performance Status (ECOG PS) ≤2, elevated lactate dehydrogenase (LDH) or previous melanoma treatments. Responses were determined locally, without central review. PFS was estimated using the Kaplan-Meier analysis and modelled with multivariate Cox model. Risk subgroups were identified using a regression tree analysis. RESULTS: Between March 2015 and November 2016, 856 patients received at least one D + T dose. Overall, 92% had stage IV melanoma, 38% ECOG PS ≥1, 32% BM and 37.5% elevated LDH. Median PFS was 8.02 months (95% confidence interval [CI] 7.33-8.77). Significant factors associated with lower PFS were ECOG PS ≥1, elevated LDH, ≥3 metastatic sites and presence of BM. Patients with <3 metastatic sites, ECOG = 0 and no BM had the highest probability of PFS at 6 months (83%, 95% CI 76-87) and 12 months (56%, 95% CI 47-64), respectively. CONCLUSIONS: This is the largest prospective study in advanced BRAF V600-mutant melanoma patients treated with D + T, conducted in conditions close to 'real-world practice'. We confirm previous findings that LDH, ECOG PS and ≥3 metastatic sites are associated with shorter PFS, but the real-world setting introduces BM as a major prognostic factor.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Saiag P, Robert C, Grob JJ, et al. Efficacy, safety and factors associated with disease progression in patients with unresectable (stage III) or distant metastatic (stage IV) BRAF V600-mutant melanoma: An open label, non-randomized, phase IIIb study of trametinib in combination with dabrafenib. Eur J Cancer. 2021. PMID: 34243078. doi:10.1016/j.ejca.2021.05.031

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。